Part of idb holding spa
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1921
Completed
1
100.0%
No approval data available
- Nestlé Health Science and IdB Holding S.p.A. have entered into a licensing agreement to develop and commercialize VOWST for preventing recurrent C. difficile infections in Europe, subject to EMA approval. - VOWST is currently the first and only FDA-approved oral live biotherapeutic product indicated to prevent recurrent C. difficile infection in adults following antibiotic treatment. - The collaboration addresses a significant unmet medical need, as recurrent C. difficile infection is a potentially life-threatening condition with limited treatment options and substantial healthcare costs. - IdB Holding will establish a dedicated company to market VOWST across European markets once regulatory approval is obtained from the European Medicines Agency.
- The pharmaceutical industry is experiencing significant growth in highly potent active pharmaceutical ingredients (HPAPIs), driven by advances in oncology and antibody-drug conjugates requiring ultra-high containment measures. - OEB 6 classification represents the highest risk category for compounds with occupational exposure limits at or below 200ng/m³, necessitating specialized manufacturing facilities and significant capital investment. - The global HPAPI market is projected to grow from $3.5 billion in 2015 to $14.65 billion by 2030, with oncology accounting for one-third of drug candidates and 25% of new chemical entities classified as highly potent. - Manufacturing OEB 6 compounds requires fully integrated containment strategies and bespoke solutions, with capacity likely concentrated among experienced manufacturers like Indena, which reports containment performance at ≤1 ng/m³.
- Indena and TCG GreenChem have announced a strategic collaboration to develop innovative payload-linkers for antibody-drug conjugates, combining Indena's high-potency API expertise with TCG GreenChem's green chemistry capabilities. - The partnership aims to reduce ADC development timelines from 18 months to 12 months between clinical candidate nomination and Phase 1 trials, addressing the growing demand from over 180 companies developing more than 1,170 ADC candidates. - The collaboration provides an integrated solution for ADC manufacturing challenges, offering faster development processes while maintaining sustainability standards through green chemistry principles and waste reduction initiatives.
